Notwithstanding continuing efforts to improve the primary treatment for ovarian cancer, most
patients will ultimately develop recurrent disease. The benefits of detection and early …

Ovarian cancer (OC) is the fifth most common cause of cancer death in women. Although
significant progress has been made in the treatment of OC, the majority of patients …

In this era of advanced medical technology, recurrent ovarian cancer continues to be a
therapeutic dilemma. Most of these patients will succumb to their disease process. For this …

Recurrence still occurs in a majority of patients with advanced ovarian cancer. However,
progress in the management has allowed a significant prolongation of survival for relapsing …

Introduction: Optimal management of recurrent ovarian cancer (ROC) remains an area of
uncertainty. An estimated 85% of patients with epithelial ovarian cancer who achieve a full …

DESPITE ADVANCES in surgery and the development of more effective chemotherapy,
epithelial ovarian cancer remains the number one cause of death from a gynecologic cancer …

The cure rate for women with ovarian cancer has not significantly changed over the past 10
years. However, overall survival from relapsed disease has shown improvement despite a …

An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission
following first-line therapy will develop recurrent disease. Although each subsequent line of …

Recurrent ovarian cancer remains a difficult disease to treat. Drugs used in the recurrent
disease setting include platinum compounds, taxanes, pegylated liposomal doxorubicin …

The majority of patients who present with epithelial ovarian cancer respond well to the initial
treatment, but will ultimately experience a recurrence of their disease. Chemotherapy can …